

CLAIMS

1. A combination of a microtubule-interfering agent and an ERK-MAP kinase cascade inhibitor wherein the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor are administered, either simultaneously or separately with a predetermined interval of time, in order to treat a tumor.
2. A combination as claimed in claim 1 wherein the microtubule-interfering agent is a tubulin polymerization inhibitor.
3. A combination as claimed in claim 2 wherein the tubulin polymerization inhibitor is dolastatin 10 or a compound analogous thereto, or vincristine or a compound analogous thereto.
4. A combination as claimed in claim 1 wherein the ERK-MAP kinase cascade inhibitor is a MAP kinase inhibitor, a MAP kinase inhibitor or a MAP kinase kinase inhibitor.
5. An antitumor agent which contains, as an active ingredient, a microtubule-interfering agent for use in combination with an ERK-MAP kinase cascade inhibitor.
6. An agent for potentiating the antitumor effect of a microtubule-interfering agent which contains an ERK-MAP kinase cascade inhibitor as an active ingredient.
7. A method for the treatment of a tumor which comprises administering a microtubule-interfering agent and an ERK-MAP kinase cascade inhibitor to a patient, either simultaneously or separately with a predetermined interval of time.
8. The use of an ERK-MAP kinase cascade inhibitor for the purpose of potentiating the antitumor effect of a microtubule-interfering agent.
9. A pharmaceutical product comprising a microtubule-interfering agent and/or an ERK-MAP kinase cascade inhibitor, the pharmaceutical product being characterized by having, on or within

09869916-070901
106020-97669860

the packaging material thereof, an indication or document showing the instruction that the microtubule-interfering agent and the ERK-MAP kinase cascade inhibitor should be used in combination.

09869916 070901
T06070 9T669860